SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®

Sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Study ID
NCT05546398
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

In this study, a survey of office-based cardiologists and lipid management specialists will be conducted on treatment decisions for NUSTENDI® (bempedoic acid 180 mg fixed dose combination \[FDC\] with ezetimibe 10 mg) followed by a retrospective chart review of patients at high and very-high cardiovascular risk with hypercholesterolemia or mixed dyslipidemia who were treated with FDC as add-on to treatment with maximally tolerated statin therapy in routine clinical practice.

Key Dates

Start date
Apr 22, 2022
Status verified
Nov 2022
Primary completion
Nov 17, 2022
Completion
Nov 17, 2022

Study Design

Enrollment
500 participants (actual)

Arms

  • Arm: Physicians
    Office-based cardiologists (OBCs) and lipid management specialists (LMSs) who are qualified for study participation regarding experience in lipid management therapy and treating a sufficient number of patients.
  • Arm: High and Very High Cardiovascular Patients
    Patients at high and very high cardiovascular risk as assessed by the office-based cardiologists and lipid management specialists with hypercholesterolemia or mixed dyslipidemia who received a prescription of bempedoic acid 180 mg fixed dose combination with ezetimibe 10 mg (FDC).

Primary Outcome Measure

Low density Lipoprotein-Cholesterol (LDL-C) Levels at Therapy Decision Based on Physician Survey [ Time Frame: Up to 6 months ]

Related Studies